These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 21476152)

  • 1. Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.
    Cooper V; Moyle GJ; Fisher M; Reilly G; Ewan J; Liu HC; Horne R;
    AIDS Care; 2011 Jun; 23(6):705-13. PubMed ID: 21476152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine.
    DeJesus E; Ruane P; McDonald C; Garcia F; Sharma S; Corales R; Ravishankar J; Khanlou H; Shamblaw D; Ecker J; Ebrahimi R; Flaherty J;
    HIV Clin Trials; 2008; 9(2):103-14. PubMed ID: 18474495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
    N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.
    Fisher M; Moyle GJ; Shahmanesh M; Orkin C; Kingston M; Wilkins E; Ewan J; Liu H; Ebrahimi R; Reilly G;
    J Acquir Immune Defic Syndr; 2009 Aug; 51(5):562-8. PubMed ID: 19561519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT).
    Arasteh K; Weitner L; Fenske S; Kuhlmann B; Freiwald M; Ebrahimi R; Gallo L; Ranneberg R; Mertenskoetter T
    Eur J Med Res; 2009 May; 14(5):195-9. PubMed ID: 19541575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study.
    Cooper V; Horne R; Gellaitry G; Vrijens B; Lange AC; Fisher M; White D
    J Acquir Immune Defic Syndr; 2010 Mar; 53(3):369-77. PubMed ID: 20087195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen.
    Rosso R; Di Biagio A; Maggiolo F; Nulvesu L; Callegaro AP; Taramasso L; Bruzzone B; Viscoli C
    AIDS Care; 2012; 24(1):54-8. PubMed ID: 21800951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
    Gianotti N; Galli L; Bocchiola B; Cahua T; Panzini P; Zandonà D; Salpietro S; Maillard M; Danise A; Pazzi A; Lazzarin A; Castagna A
    HIV Med; 2013 Mar; 14(3):153-60. PubMed ID: 22994659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
    Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M
    Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
    Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
    Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
    Post FA; Moyle GJ; Stellbrink HJ; Domingo P; Podzamczer D; Fisher M; Norden AG; Cavassini M; Rieger A; Khuong-Josses MA; Branco T; Pearce HC; Givens N; Vavro C; Lim ML
    J Acquir Immune Defic Syndr; 2010 Sep; 55(1):49-57. PubMed ID: 20431394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efavirenz in fixed combination with tenofovir and emtricitabine. Long-term effectiveness verified in new studies].
    Wepner U
    MMW Fortschr Med; 2011 May; 153(18):20-1. PubMed ID: 21604586
    [No Abstract]   [Full Text] [Related]  

  • 16. [Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of patients infected with HIV-1].
    Oyagüez I; Casado MA; Cotarelo M; Ramírez-Arellano A; Mallolas J
    Farm Hosp; 2009; 33(5):247-56. PubMed ID: 19775575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
    J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simplified combination antiretroviral therapy regimen enhances adherence, treatment satisfaction and quality of life: results of a randomized clinical trial.
    Langebeek N; Sprenger HG; Gisolf EH; Reiss P; Sprangers MA; Legrand J; Richter C; Nieuwkerk PT
    HIV Med; 2014 May; 15(5):286-90. PubMed ID: 24215485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India.
    Pujari S; Dravid A; Gupte N; Joshi K; Bele V
    Medscape J Med; 2008; 10(8):196. PubMed ID: 18924648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.